Use of proteasome inhibitors to treat dry eye disorders

Details Use of proteasome inhibitors to treat dry eye disorders Use of proteasome inhibitors to treat dry eye disorders

2006-09-26

2006-09-26

Fay, Zohreh (Department: 1618)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

C514S912000

Reexamination Certificate

active

07112588

ABSTRACT:
Proteasome inhibitors are useful for treating dry eye disorders and other disorders requiring the wetting of the eye.

REFERENCES:
patent: 3991759 (1976-11-01), Urquhart
patent: 4131651 (1978-12-01), Shah et al.
patent: 4370325 (1983-01-01), Packman
patent: 4409205 (1983-10-01), Shively
patent: 4744980 (1988-05-01), Holly
patent: 4804539 (1989-02-01), Guo et al.
patent: 4818537 (1989-04-01), Guo
patent: 4883658 (1989-11-01), Holly
patent: 4914088 (1990-04-01), Glonek et al.
patent: 4966773 (1990-10-01), Gressel et al.
patent: 5041434 (1991-08-01), Lubkin
patent: 5075104 (1991-12-01), Gressel et al.
patent: 5174988 (1992-12-01), Mautone et al.
patent: 5278151 (1994-01-01), Korb et al.
patent: 5290572 (1994-03-01), MacKeen
patent: 5294607 (1994-03-01), Glonek et al.
patent: 5371108 (1994-12-01), Korb et al.
patent: 5403841 (1995-04-01), Lang et al.
patent: 5578586 (1996-11-01), Glonek et al.
patent: 5620921 (1997-04-01), Sullivan
patent: 5677335 (1997-10-01), Robertson et al.
patent: 5696166 (1997-12-01), Yanni et al.
patent: 5800807 (1998-09-01), Hu et al.
patent: 5958912 (1999-09-01), Sullivan
patent: 6071904 (2000-06-01), Ali et al.
patent: 6083903 (2000-07-01), Adams et al.
patent: 6096733 (2000-08-01), Lubkin
patent: 6107289 (2000-08-01), Sullivan
patent: 6153607 (2000-11-01), Pflugfelder et al.
patent: 10036289 (1998-02-01), None
patent: WO 95/31211 (1995-11-01), None
patent: WO 96/32105 (1996-10-01), None
patent: WO 98/35691 (1998-08-01), None
patent: WO 99/15183 (1999-04-01), None
patent: WO 99/22729 (1999-05-01), None
patent: WO 00/03705 (2000-01-01), None
patent: WO 00/43000 (2000-07-01), None
patent: WO 00/61168 (2000-10-01), None
patent: WO 00/64863 (2000-11-01), None
Adams, “Proteasome Inhibitors as Therapeutic Agents” Expert Opinion in Therapeutic Patients, vol. 13(1), pp. 45-57 (2003).
Brignole et al., “Flow cytometric analysis of inflammatory markers in conjjnctival epithelial cells of patients with dry eyes,” Database Medicine 'Online! May 2000; Database accession No. NLM10798650 XP002215304 abstract &Investivative Ophthalmology&Visual Science. United States, May 2000, vol. 41(6) pp. 1356-1363.
Corey et al., Total Synthesis and Biological Activity of Lactacystin, Omuralide and Analogs,Chem. Pharm. Bull., vol. 47, pp. 1-10 (1999).
Dou, et al., “Pharmacological proteasome inhibitors and their therapeutic potential,”Exp. Opin. Ther. Patents, vol. 10(8); pp. 1263-1272 (2000).
Dou, et al., “Proteasome inhibitors as potential novel anticancer agents,”Drug Resistance Updates, vol. 2, pp. 215-223 (1999).
Elliott et al., “Proteasome inhibition: A novel mechanism to combat asthma,”J. Of Allergy and Clinical Immunology, vol. 104(2);pp. 294-300 Aug. 1999.
Groettrup et al., “Selective proteasome inhibitors: modulators of antigen presentation?,”DDT, vol. 4(2), pp. 63-71 (1999).
Iqbal, et al., “Proteasone inhibitors,”High Throughput Screening for Novel Anti-Inflammatories, edited by M. Kahn, pp. 19-34 (2000).
Kisselev, et al., “Proteasome inhibitors: from research tools to drug candidates,”Chemistry&Biology, vol. 8, pp. 739-758 (2001).
Lee, et al., “Proteasome Inhibitors: valuable new tools for cell biologists,”Cell Biology, vol. 8, p. 397-403 (1998).
Lemp et al., “Evaluation and differential diagnosis of keratoconjunctivitis sicca,” Database Medline 'Online! Dec. 2000; Database accession No. NLM11128698 XP002215303 abstract &The Journal of Rheumatology, Supplement. Canada Dec. 2000, pp. 11-14.
Lemp, “Report of the National Eye Institute/Industry Workshop on Clinical Trials in Dry Eyes,”CLAO Journal, vol. 21(4), pp. 221-231 (1995).
McCulley et al., “Tear Film Structure and Dry Eye,”Contactologiavol. 20, pp. 145-149 (1998).
Marsh et al., “Topical Nonpreserved Methylprednisolone Therapy for Keratoconjunctivitis Sicca in Sjogren Syndrome,”Ophthalmology, vol. 106(4), pp. 811-816 (1999).
Myung, et al., “The Ubiquitin-Proteasome Pathway and Proteasome Inhibitors,”Medicinal Research Reviews, vol. 21(4), pp. 245-273 (2001).
Shine et al., “Keratoconjunctivitis Sicca Associated with Meibomian Secretion Polar Lipid Abnormality,”Arch. Ophthalmol.vol. 116, pp. 849-852 (1998).
Soucy et al., “A Novel and Efficient Synthesis of a Highly Active Analogue ofclasto-Lactacystin β-Lactone,”J. Am. Chem. Soc, vol. 121, pp. 9967-9976 (1999).
Tauber et al., “Lacrimal Gland, Tear Film and Dry Eye Syndromes,”J. Adv. Exp. Med. Biology, vol. 438, pp. (1998).
Wang et al., “Suppressionof NK-kappaβ-dependent proinflammatory gene expression in human RPE cells by a proteasome inhibitor,”Investigative Ophthalmoogy&Visual Science, vol. 40(2), pp. 477-486 (1999).

Affiliated with

Also associated with

Rating

Use of proteasome inhibitors to treat dry eye disorders does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Use of proteasome inhibitors to treat dry eye disorders, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of proteasome inhibitors to treat dry eye disorders will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3615783